Integrating immunopeptidomics with liquid biopsy for precision oncology
Combining tumor DNA detection with immune-peptide profiling could enable continuous monitoring of cancer without repeated biopsies.
This perspective review proposes combining immunopeptidomics — profiling HLA-bound peptides — with minimally invasive liquid biopsy materials (CTCs, EVs, cfDNA) to enable dynamic, patient-specific neoantigen surveillance without repeated tumor biopsies. The integration could expand precision oncology by continuously monitoring antigen presentation for personalized immunotherapy development.
What the study was
- Study design
- Narrative review
- Population
- Cancer patients (general; focus on immunotherapy-eligible populations)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Molecular Aspects of Medicine
Why it surfaced
Conceptually forward-looking review bridging liquid biopsy and immunopeptidomics. Relevant as methodological context for both liquid biopsy and immunotherapy topics. Design quality scored 0 (review).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.